Changes in MDS-UPDRS after treatment with 10mg or 20mg buntanetap in patients with a PD diagnosis over 3 years compared to baseline and placebo MALVERN, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- via IBN ...
Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a very ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results